Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05116189 |
| Title | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) |
| Recruitment | Active, not recruiting |
| Gender | female |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme Corp. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | TUR | POL | NZL | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | DNK | DEU | CAN | BRA | BEL | AUS |